Investor Presentaiton

IBI-302 (VEGF/Complement): First-in-Class Bispecific Fusion Protein Blocking VEGF/Complement Proteins IBI-302 Differentiated Advantages • High affinity blocker of VEGF family and complement proteins that simultaneously inhibit angiogenesis and inflammation pathways • • . low IBI-302 is constructed by domains of human VEGFR1/2 and CR1 on the human IgG1 backbone; Fully human sequence with immunogenicity risk IBI-302 has the potential effect in retinal fibrosis and macular atrophy Primary outcomes of Ph1b Change of BCVA-ETDRS letters 25 20' 15- = 10. 5 0 Clinical Highlights BCVA Week • • Clinical Highlights Phase 1 data published at 2020 AAO: good safety and tolerability with promising effect Improved visual acuity and reduction of retinal edema at post- injection one week BCVA increased by 8 letters on average for 4mg group at week 12 and effect lasts about 8~12 weeks after three loading injections Average central retinal thickness decreased by 134μm at week 12 IBI-302 Development Program Overview Clinical • progress • • Completed Phase 1a study for wet AMD in 1H 2020 Completed patient enrolment of Phase 1b study for wet AMD in China in 1H 2021 Presented Phase 1 study results at AAO in Nov 2020 2mg IBI302 4mg IBI302 Aflibercept 2021 plan 20 BCVA: best corrected visual acuity To start Phase 2 trial in wet AMD in 1H 2021 In 2021, plan to start Phase 1b/2 trial for the treatment of diabetic macular edema Plan to present the clinical results of the Phase 1b study in wet AMD at academic meeting in 2H 2021 Global first anti-VEGF/anti-complement bispecific molecule designed to potentially address huge unmet medical needs in AMD and other ophthalmology diseases with poor response or declining effect under current anti-VEGF treatment. Good safety and tolerability, promising effect observed in Phase 1. Innovent Confidential Copyright©2021 Innovent Biologics 28

View entire presentation